[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643500":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":33,"centralContacts":38,"locations":44,"responsibleParty":61,"collaborators":33,"id":63,"slug":33,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":33,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":33,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":33,"overallStatus":82,"whyStopped":33,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Hutchmed","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment A","EXPERIMENTAL","All participants in treatment A will fast overnight for at least 10 hours prior to HMPL-760 dosing.",[13],"Drug: HMPL-760",{"label":15,"type":10,"description":16,"interventionNames":17},"Treatment B","All participants in treatment B will receive a standardized high-fat meal approximately 30 minutes before HMPL-760 administration",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Treatment C","All participants in treatment C will receive a standardized low-fat meal approximately 30 minutes before HMPL-760 administration",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Treatment D","All participants receive rabeprazole 20 mg orally QD 1 h before the breakfast on Day 15 and the morning of Day 16 to Day 20. Rabeprazole and HMPL-760 are orally administered concomitantly under fasted conditions on the morning of Day 21.",[26],"Drug: Rabeprazole and HMPL-760",[28,34],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","HMPL-760","300 mg HMPL-760 will be administered orally once daily on Day 1, Day 6 and Day 11.",[9,15,19],null,{"type":29,"name":35,"description":36,"armGroupLabels":37,"otherNames":33},"Rabeprazole and HMPL-760","20 mg of rabeprazole will be administered orally once daily in the morning from Day 15 to Day 21, and a 300 mg oral dose of HMPL-760 will be administered concomitantly with rabeprazole on Day21.",[23],[39],{"name":40,"role":41,"phone":42,"phoneExt":33,"email":43},"Tianyun Li","CONTACT","(+86) 13037313645","tianyunl@hutch-med.com",[45],{"facility":46,"status":33,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Shanghai Xuhui Central Hospital","Shanghai","Shanghai Municipality","200031","China","CN",{"type":53,"coordinates":54},"Point",[55,56],121.45806,31.22222,{"lat":56,"lon":55},[59],{"name":60,"role":41,"phone":33,"phoneExt":33,"email":33},"Yanmei Liu, Doctor",{"type":62,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100643500",false,"NCT07643272","A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules","An Open-Label, Randomized, Four-Period, Six-Sequence Phase I Study to Evaluate the Effect of Food and Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of HMPL-760 Capsules in Healthy Participants","Inclusion Criteria:\n\n1. Participants are fully aware of this study and voluntarily sign the ICF.\n2. Male or female aged 18 to 45 years old (inclusive).\n3. Participant's body mass index (BMI) at screening: 18 kg\u002Fm2 \\\u003C BMI ≤ 29.9 kg\u002Fm2 and weight ≥ 50 kg for males and ≥ 45 kg for females.\n4. Participant is willing and able to comply with the protocol in all aspects.\n\nExclusion Criteria:\n\n1. Known history of any gastrointestinal surgery or any condition that could affect drug absorption (e.g., cholecystectomy, achlorhydria, peptic ulcer disease, gastric\u002Fintestinal surgery or history of resection; prior appendectomy or hernia repair is allowed).\n2. Clinically significant disease within 8 weeks prior to the first dose or clinically significant infection within 4 weeks prior to the first dose.\n3. Clinically significant abnormal findings in physical examination, vital signs, or laboratory tests at screening.\n4. Systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg at screening.\n5. Participants who smoked over 10 cigarettes daily within 3 months before screening.",true,"ALL","18 Years","45 Years",{"count":74,"type":75},24,"ESTIMATED","INTERVENTIONAL",[78],"PHASE1","This is a single-center, open-label, randomized, four-period, six-sequence study with a planned enrollment of 24 healthy participants. The study consists of a screening period, a dosing period (Cycles 1, 2, 3, and 4), and a follow-up period. Screening must occur within 14 days prior to the first dose of study drug. Enrolled participants will be randomly assigned to one of 6 dosing sequences in the ratio of 1:1:1:1:1:1 to complete Cycles 1-3 dosing to evaluate the effect of different types of food on the PK of HMPL-760, and then to receive rabeprazole and HMPL-760 in Cycle 4 to assess the effect of PPI on the PK of HMPL-760 (see dosing sequence table for details).",[81],"Healthy Participants","NOT_YET_RECRUITING","2026-06-08",{"date":85,"type":86},"2026-06-11","ACTUAL",{"date":88,"type":75},"2026-06",{"date":90,"type":75},"2026-12",{"name":5,"class":6},1]